A major milestone on March 14th 2025 advanced the EU Trilogue discussions aimed to complete the final text of the New Genomic Techniques (NGTs) or gene editing legislation for the EU; California Rice Commission approved Cibus' field research proposal marking the first time gene edited Rice has been authorized for planting within the state Advancing Rice herbicide tolerance trait commercialization efforts: affirmed strategic collaboration with Albaugh LLC and RTDC Corporation Limited continues to strengthen weed management solutions pipeline as Cibus continues development with four major seed company customers Sclerotinia (White Mold) resistance trait development continues progress with fou

Legislation aims to adapt EU law to reflect scientific and technological progress, enabling the products of New Genomic Techniques (NGTs), such as gene editing, to contribute to more sustainable agriculture, climate resilience, and food security Proposed legislation identifies a ‘conventional-like' category of NGT-1 products that would be regulated as conventional varieties, bringing EU regulation closer to that of other global trading partners The agreement on the Council's negotiating mandate allows its presidency to start negotiations with the European Parliament on the final text of the regulation SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company

SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report fourth quarter 2024 financial results on Thursday, March 20, 2025. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. Fourth Quarter 2024 Results Conference Call Event Date: Thursday, March 20, 2025         Time: 4:30 p.m. ET         Participant Numbers: +1-877-300-8521 (U.S.), +1-412-317

Initial bioassay data for Cibus' third mode of action for white mold (Sclerotinia) resistance trait in canola shows promising results in controlled environment assessment Cibus' white mold resistance traits are expected to help preserve crop yields and reduce fungicide usage for farmers SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that controlled environment testing of its third mode of action (MOA) for its Sclerotinia resistance trait in Canola demonstrated enhanced resistance. The core of Cibus' gene editing tech

SAN DIEGO, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company" or "Cibus"), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced key leadership changes pursuant to the Company's succession planning strategy. The Board has accepted Rory Riggs' resignation as the Company's Chief Executive Officer. Peter Beetham, the Company's President and Chief Operating Officer, also will serve as the Company's Interim Chief Executive Officer. Dr. Beetham is a co-founder of Cibus Global with Mr. Riggs and with Greg Gocal, who will remain the Company's Chief Scientific Officer. Mr. Riggs will remain Chairman

SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company" or "Cibus"), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today issued a correction relating to the rice conversion rates previously disclosed in its January 16, 2025 press release. The Company has concluded that the gene editing conversion rates of 10-25% in Rice have not been reconfirmed based upon subsequent experiments and high variability in the conversion rate data. Cibus is continuing to advance its oligonucleotide directed mutagenesis (ODM) editing technologies to drive improved editing conversion rates across its developed trai

EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company"), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that Rory Riggs, Co-Founder, Chief Executive Officer, and Chairman, and Peter Beetham, Co-Founder, President, and Chief Operating Officer, will host a presentation at the Sidoti Micro Cap Conference. Presentation detailsDate: Thursday, January 23, 2025Time: 1:45 p.m. ET (10:45 a.m. PT)         Webcast link: https://sidoti.zoom.us/webinar/register/WN_zgpeW_rJSbS6UDdU4sskZQ About Cibus Cibus is a leader in gene edited produc

SAN DIEGO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company" or "Cibus"), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced it has entered into securities purchase agreements with existing investors of the Company, including institutional and strategic investors, as well as with the Company's CEO, Rory Riggs, for the purchase and sale of 9,040,000 shares of its Class A Common Stock (inclusive of pre-funded warrants to purchase shares of Class A Common Stock, in lieu of common stock), and warrants to purchase up to an aggregate of 9,040,

Culmination of Advances in Gene Editing Efficiency and Process Improvements Drives Standardization of Cibus' Gene Editing System Delivering Traits in a Customer's Elite Germplasm in less than 12 Months Cibus Announces Editing Milestone in the Continuing Development of its Soybean Platform SAN DIEGO, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that it has established production standards for its proprietary RTDS gene editing process. These standards, applicable to the Company's developed and advanced traits, represent the accom

Alliance Global Partners initiated coverage of Cibus Global with a rating of Buy and set a new price target of $25.00

Canaccord Genuity resumed coverage of Cibus Global with a rating of Buy and set a new price target of $22.00

H.C. Wainwright initiated coverage of Cibus Global with a rating of Buy and set a new price target of $25.00

Canaccord Genuity resumed coverage of Cibus Global with a rating of Buy and set a new price target of $30.00

4 - Cibus, Inc. (0001705843) (Issuer)

3 - Cibus, Inc. (0001705843) (Issuer)

4 - Cibus, Inc. (0001705843) (Issuer)

3 - Cibus, Inc. (0001705843) (Issuer)

4 - Cibus, Inc. (0001705843) (Issuer)

4 - Cibus, Inc. (0001705843) (Issuer)

4 - Cibus, Inc. (0001705843) (Issuer)

4 - Cibus, Inc. (0001705843) (Issuer)

4 - Cibus, Inc. (0001705843) (Issuer)

4 - Cibus, Inc. (0001705843) (Issuer)

PRE 14A - Cibus, Inc. (0001705843) (Filer)

8-K/A - Cibus, Inc. (0001705843) (Filer)

S-8 - Cibus, Inc. (0001705843) (Filer)

10-K - Cibus, Inc. (0001705843) (Filer)

8-K - Cibus, Inc. (0001705843) (Filer)

8-K - Cibus, Inc. (0001705843) (Filer)

8-K - Cibus, Inc. (0001705843) (Filer)

424B5 - Cibus, Inc. (0001705843) (Filer)

8-K - Cibus, Inc. (0001705843) (Filer)

8-K - Cibus, Inc. (0001705843) (Filer)

EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

Cibus Announces Election of New Board Member, Deepening Strategic Leadership and Experience SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a global leader in Gene Editing in agriculture and the development of Productivity Traits in plants that directly impact farming productivity and profitability announced that its Board of Directors has elected Jim Collins, former CEO of Corteva, to the Board. "Jim brings to Cibus immense knowledge and strategic vision on the direction of the future role and use of Gene Editing in agriculture," said Mark Finn, Chair of the Audit Committee. "Jim's experience leading one of the largest agricultural and seed companies will gi

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, announced today the appointment of Steve Berreth as General Counsel and Corporate Secretary for the corporation. Mr. Berreth was previously Vice President, General Counsel and Secretary for Syngenta Crop Protection LLC, the North American Subsidiary of Syngenta AG, one of the world's largest biotechnology agribusinesses and one of the largest crop protection chemical and seed businesses in the world. He was a member of the Syngenta global legal and compliance leadership teams and led the North American le

SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report fourth quarter 2024 financial results on Thursday, March 20, 2025. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. Fourth Quarter 2024 Results Conference Call Event Date: Thursday, March 20, 2025         Time: 4:30 p.m. ET         Participant Numbers: +1-877-300-8521 (U.S.), +1-412-317

Announced a strategic realignment to advance commercial opportunities, focusing resources on advancement of weed management platform (HT1 and HT3) for Rice, Pod Shatter Reduction in Canola, Sclerotinia resistance for Canola and Soybean, and on Soybean platform development Great progress in Rice as we execute on our agreements with four major seed company customers in the United States and Latin America, with germplasm received from all customers; completed successful field trials with HT3 in customer germplasm, as well as completed what the Company believes to be the first field trials for stacked gene-edited herbicide tolerance traits Also in Rice, signed an Agreement with RTDC Corporatio

SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that the company will report third quarter 2024 financial results on Thursday, November 7, 2024. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. Third Quarter 2024 Results Conference Call Event Date: Thursday, November 7, 2024         Time: 4:30 p.m. ET         Participant Numbers: +1-877-300-8521 (U.S.), +1-412-317-6026 (International)         Event Link: https:/

Demonstrated continued momentum securing an agreement for its Herbicide Tolerance (HT) traits in Rice with a fourth customer in the second quarter with signing of agreement with Federacion Nacional de Arroceros ("FEDEARROZ"); builds on prior agreements with Loveland Products, Inc., a subsidiary of Nutrien, Ltd., in the United States and with Interoc S.A. in Latin America Rice platform is the Company's first entry into the major global grain crops with significant potential commercial opportunities Wheat platform operational, enables Cibus access into the largest global grain crop in planted acres Continued achievement of milestones in the development of its Advanced Trai

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that the company will report second quarter 2024 financial results on Thursday, August 8, 2024. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. Second Quarter 2024 Results Conference Call Event Date: Thursday, August 8, 2024         Time: 4:30 p.m. ET         Participant Numbers: +1-800-343-5172 (U.S.), +1-203-518-9856 (International)The conference ID "CIBUS" or 2

Important EU Parliament vote on gene editing continues global momentum for the approval of new genomic techniques (NGTs) as similar to conventional breeding Completed single cell regeneration platform for Wheat – with Canola & Rice, Cibus now has its semi-automated crop platform operational for 3 of the top 5 major crops Signed three agreements in Rice including with Loveland Products Inc., a subsidiary of Nutrien Ltd., and Interoc S.A., for Cibus' two proprietary Herbicide Tolerance traits (HT1 and HT3) Continued progress with customers toward commercializing Pod Shatter Reduction (PSR) trait in Canola Continues to demonstrate commercial-level trait performance following successful seas

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report first quarter 2024 financial results on Thursday, May 9, 2024. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. First Quarter 2024 Results Conference Call Event Date: Thursday, May 9, 2024         Time: 4:30 p.m. ET         Participant Numbers: +1-877-704-4453 (U.S.), +1-201-389-0920

SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report fourth quarter 2023 financial results on Thursday, March 21, 2024. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. Fourth Quarter 2023 Results Conference Call Event Date: Thursday, March 21, 2024Time: 4:30 p.m. ETParticipant Numbers: +1-877-704-4453 (U.S.), +1-201-389-0920 (Internation

During the 2023 field season, Cibus completed extensive field trials for its three developed traits, PSR in canola and HT1 and HT3 in rice. Company also reports continued progress of Cibus' high-throughput soybean editing system and its two advanced traits for Sclerotinia resistance and HT2. Initial UK field trials for its PSR trait in WOSR are underway in conjunction with positive tailwinds in European regulatory progress; accelerating Cibus' PSR trait in the European market. Launched strategic realignment and cost savings initiatives to direct focus towards advancing late-stage activities, aligning with its primary commercial objectives. Management to host a conference call webcast Thu

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a global leader in gene editing in agriculture and the development of productivity traits in plants, today announced that the Company will report third quarter 2023 financial results on Thursday, November 9, 2023. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. Third Quarter 2023 Results Conference CallEvent Date: Thursday, November 9, 2023Time: 4:30 p.m. ETParticipant Numbers: +1-877-243-8548 (U.S.), +1-312-281-2974 (International)Event Link: https://investor.cibus.com/events For interested